The plant-derived, diterpenoid 7-keto-sempervirol was recently reported to display moderate activity against larval stages of Schistosoma mansoni (IC 50 = 19.1 µM) and Fasciola hepatica (IC 50 = 17.7 µM), two related parasitic blood and liver flukes responsible for the neglected tropical diseases schistosomiasis and fascioliasis, respectively. Here, we aimed to increase the potency of 7-keto-sempervirol by total synthesis of 30 structural analogues. Subsequent screening of these new diterpenoids against juvenile and adult lifecycle stages of both parasites as well as the human HepG2 liver cell line and the bovine MDBK kidney cell line revealed structure-activity relationship trends. The most active analogue, 7d, displayed improved dual anthelmintic activity over 7-keto-sempervirol (IC 50 ≈ 6 µM for larval blood flukes; IC 50 ≈ 3 µM for juvenile liver flukes) and moderate selectivity (SI ≈ 4 -5 for blood flukes, 8 -13 for liver flukes compared to HepG2 and MDBK cells, respectively). Phenotypic studies using scanning electron microscopy revealed substantial tegumental alterations in both helminth species, supporting the hypothesis that the parasite surface is one of the main targets of this family of molecules. Further modifications of 7d could lead to greater potency and selectivity metrics resulting in a new class of broad-spectrum anthelmintic.
Introduction
Schistosomiasis, caused by infection with blood fluke schistosomes, is the most devastating human parasitic disease after malaria considering the number of people currently infected and at risk of infection [1] . It is a chronic disease of poverty characterized by pain and disability that, collectively, exacerbates the already compromised healthcare situation of developing tropical countries [2] . The number of people infected is approximately 600 million [3] and, along with 300 thousand deaths per year, schistosomiasis is considered as the most deadly neglected tropical disease (NTD) [4] . No vaccines are available to prevent infection and, therefore, treatment of infected individuals is predominantly facilitated by chemotherapy with praziquantel (PZQ) ( Figure 1A ). PZQ is active against adult worms of all Schistosoma species, but less effective against the immature forms, leading easily to reinfections [5] ;
moreover, due to its large scale administration, concerns about drug resistance are increasing [5, 6] .
Another NTD predominantly controlled by a single drug, triclabendazole, is fascioliasis.
Ingestion of liver fluke parasites initiates fascioliasis and leads to up to 17 million human [7] and numerous livestock animal infections per annum, causing enormous economic losses in the global beef, lamb and milk industries [8] . In the United Kingdom alone, an estimated £23 million is lost annually due to fascioliasis [9] . However, recent reports suggest that this figure could rapidly increase due to changes in global climate and extensive animal movement [10, 11] . Triclabendazole ( Figure 1B ) is the only commercially available drug that is active against both juvenile and adult liver fluke lifecycle stages. Unfortunately, triclabendazole resistant Fasciola parasites have been described throughout Asia, Africa, South America, North America, Australia and Europe [12] , making the discovery of new drugs for combating this human and animal disease an urgent healthcare priority.
For these reasons, research into the discovery of new anti-flukicidal drugs is increasing with natural products being an exceptionally attractive resource for beginning such a process [13] . Indeed, plant-derived natural products are a well-recognised source of anti-infective compounds due to natural selection shaping the production of more toxic and protective
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4 compounds to facilitate survival in a microorganisms-rich environment [14] . One example of a plant-derived compound isolated from Lycium chinense with bioactivity against both Schistosoma mansoni and Fasciola hepatica is the diterpenoid 7-keto-sempervirol ( Figure   1C ) [15] . While this diterpenoid was only moderately potent, it was effective in killing juvenile and adult forms of both fluke species. Considering the fact that some endemic areas for schistosomiasis are co-endemic for fascioliasis and that, in these areas, it is common to find people with both infections [16] [17] [18] , a compound with potent dual anthelmintic activity against multiple lifecycle stages would be highly desirable. In this study, 7-keto-sempervirol was subjected to medicinal chemistry optimisation, with the aim of exploring whether different substitutions could increase the dual anthelmintic potency of this natural product. To achieve this, structural related analogues were obtained by total synthesis using the different synthetic pathways reported here. The compounds were subsequently screened against larval (schistosomula) and adult S. mansoni blood flukes as well as against newly excysted juvenile (NEJs), immature and adult F. hepatica liver flukes.
The newly synthesised compounds were also screened against HepG2 liver human cells and MDBK kidney bovine cells to assess potency and selectivity as well as to deduce preliminary structure activity relationships (SARs). The results of compound synthesis and bioactivities are presented and discussed here.
Results and Discussion

Chemistry
Based on the previously reported anthelmintic activity of the diterpenoid 7-keto-sempervirol, we investigated the impact of chemical structure modification on activity to obtain more potent and selective analogues. To achieve this, six families of compounds containing the basic scaffold of 7-keto-sempervirol were synthesised with each family containing distinct aromatic substitutions (Figure 2 ). Diverse synthetic strategies were adopted for each family. Non-cyclised analogues lacking bond C9-C10 were obtained from the coupling between commercially available betacyclocitral and substituted benzyl chlorides, as described by Huang et al. [19] , to generate the first set of analogues as secondary alcohols (1a-f) (Scheme 1). Corresponding ketoanalogues (2a-f) were then obtained by oxidation in the presence of tetrapropylammonium perruthenate (TPAP) and N-methylmorpholine N-oxide (NMO) (Scheme 1).
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6 Scheme 1. Synthesis of diterpenoid analogues 1a-f and 2a-f. The scheme shows the synthesis of the non-cyclised analogues 1a-f and 2a-f from beta-cyclocitral using lithiation and oxidation chemistry.
From the synthesised keto-analogues, two different cyclization methods were performed to obtain the tricyclic diterpenoid scaffold with a keto-group in position six (Scheme 2). The first method (Scheme 2A) used the Lewis acid BBr 3 to facilitate the synthesis of the trans diastereoisomers (3a-c) as described by Huang et al. [19] , while the second method (Scheme 2B) used RuCl 3 and AgOTf to obtain the cis diastereoisomer (4a-c), according to the method of Youn et al. [20] . However, this set of compounds showed instability when exposed to oxygen at room temperature and, therefore, their biological activity was not measured. Indeed, changes in colour and composition of the 6-keto compounds were observed as quickly as two (and up to seven) days post synthesis (See Supplementary information). Analysis of the resulting mixtures revealed high levels of autoxidation (cis > trans) that, upon subsequent purification and characterization, revealed the presence of a keto group in positions 6 and 7 (Scheme 2C). These 6,7-diketo derivatives (5a-c) were more stable than the original 6-keto compounds and, for this reason, are considered a new family of analogues. Literature precedent for spontaneous oxidation in terpene-based systems, including mechanistic studies, is known [21] .
Scheme 2. Synthesis of diterpenoid analogues 3a-c and 5a-c. The scheme shows the synthesis of 6-keto (3a-c) and 6,7-diketo (5a-c) analogues based on diastereoselective ring closure and subsequent autoxidation of the cis-isomer.
The other three families of compounds were obtained from one synthetic pathway according to the method described by Surendra and Corey [22] For our studies we made use of the commercially available chiral ligand (R)-BINOL, as opposed to the o,o'-dichloro-BINOL employed by Surendra and Corey in their reported enantioselective synthesis [22] . Preliminary polarimeter analysis of our final compounds 8a-d indicated enantiomeric excesses (ee's) in the range of 20-30% (data not shown). For the purpose of this screening analysis, these compounds should be treated as racemic (as is the case of the standard of care drug praziquantel [5] ). Enantiomeric synthesis and/or enantiomer resolution to study the contributory biological activity of single enantiomers will form the basis of future studies. 
Biological activities
assayed larva is considered a hit [25] . As all compounds tested were hits at 50 µM (data not shown), subsequent schistosomula screens were performed at 25 and 10 µM (Figure 3 ). Figure 3 . Diterpenoid screening on S. mansoni schistosomula. Schistosome (n = 120) / diterpenoid co-cultures were incubated for 72 hr at 37 °C in a humidified atmosphere containing 5% CO 2 . The effect that each of these diterpenoids had on schistosomula phenotype and motility at 25 µM (A) and 10 µM (B) is illustrated and compared with the negative (DMSO) and the positive controls (Auranofin). Compounds are scored by the high throughput platform Roboworm according to their effect on schistosomula phenotype and motility (indicated by change in red outlines on figures). Hit compounds (within the hit threshold) affect ≥ 70% of the larvae. Each point represents the average score of two replicates. Z'-scores [26] were calculated for these anti-schistosomula screens and included values corresponding to 0.69159 for phenotype and 0.48074 for motility. Images of the parasites after treatment with the controls and the six hits at 25 µM are also shown (C). *Result from a separate assay where the anthelmintic activity of 7-keto-sempervirol (7ks) was assessed.
The gold thiolate anti-parasitic compound Auranofin was used as a positive control [27] . At 25 µM, six compounds (2c, 2d, 5a, 5b, 7d and 8c) were considered hits and at 10 µM, only compound 7d was still active. This compound was later screened at 1 µM but showed no anti-schistosomula activity (data not shown). The estimated IC 50 values for 7d phenotype and motility were 6.8 and 6.3 µM, respectively and represent the most potent values when compared to all other analogues ( Table 1) . 
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A general observation was that most of the diterpenoids screened had a greater effect on schistosomula motility rather than phenotype. The lead compound 7-keto-sempervirol (7ks) was additionally screened by Roboworm and the anthelmintic activity, previously quantified by a different method [15] , was comparable.
The six compounds active against schistosomula at 25 µM were subsequently screened on adult male and female worm pairs (Table 1) . Amongst these six, the most active analogue was again 7d, able to kill all parasites at 50 µM and to significantly affect their motility until 12.5 µM ( Figure 4 ). While there was no significant variation in the ability of 7d to differentially affect male and female worm motility, the compound inhibited egg production even at the lowest concentration tested, 6.25 µM ( Figure 4A ; for adult worm screening of the other compounds, see Supplementary Information, S1). At this concentration, only eggs with abnormal phenotypes were found; these phenotypes (when compared to eggs from control wells) included smaller eggs lacking both lateral spines and regular autofluorescence ( Figure   4B and C). While the significance of abnormally produced eggs is currently unknown, the substantial 'anti-fecundity' activity is noteworthy as schistosome eggs are responsible for transmission in endemic areas and are the major cause of schistosomiasis-attributable chronic disease in infected humans [6] . Adult schistosome worm pairs (3 pairs / well) were co-cultivated with 7d (50 µM -6.25 µM) for 72 hr at 37 °C in a humidified atmosphere containing 5% CO 2 . The effect that 7d had on schistosome motility and egg production was quantified according to the methodologies. Each bar represents the mean motility score ± SD of 12 adult worms (6 worms x 2 independent experiments) when treated with different concentrations and compared to the negative (DMSO) and positive control (Auranofin). The overlying line graph represents the mean egg count ± SD. * Significant difference compared to DMSO controls (p < 0.05). Egg images obtained by fluorescence microscopy are also shown (under natural light in the left panels and using a GFP filter in the right panels). Eggs collected from control wells (B) are oval, contain a lateral spine and exhibit a homogeneous auto-fluorescent surface. Eggs collected from treatment wells (6.25 µM 7d) are abnormally shaped (C), smaller and are characterised by loss of the lateral spine and irregular auto-fluorescence.
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The six most active compounds on schistosomula (2c, 2d, 5a, 5b, 7d and 8c) were also screened against the related trematode, F. hepatica ( Figure 5 ). Initial screening on F.
hepatica newly excysted juveniles (NEJs) was performed at 25 and 12.5 µM and demonstrated that, similarly to schistosomula, the most active anti-NEJ compounds were 7d
and 8c ( Figure 5A and 5B).
13 Figure 5 . Anthelmintic screening of diterpenoids on F. hepatica newly excysted juveniles (NEJs). NEJs (n = 25) / diterpenoid co-cultures were incubated for 72 hr at 37 °C in a humidified atmosphere containing 5% CO 2 . The effect that each of these diterpenoids had on NEJ phenotype and motility at 25 µM (A) and 12.5 µM (B) is illustrated and compared with the negative (DMSO) and the positive controls (Triclabendazole). Each bar graphs represents the average score ± SD (n = 25) for phenotype (green) and motility (blue). Compounds 7d and 8c showed the greatest significant activity at the lowest test concentration. Images of the parasites after treatment with the controls and the 2 hits at 12.5 µM are also shown (C). * Significant difference with DMSO control (p < 0.05).
Subsequently, titrations of these two compounds (and of 7ks as reference compound) allowed the calculation of the respective IC 50 s, with 7d exhibiting values of 3.2 and 2.5 µM for phenotype and motility (Table 2) C in a humidified atmosphere containing 5% CO 2 . The effect that the compounds had on the immature (A) and adult (B) parasites was quantified according to the methodologies. Each bar represents the mean motility score ± SD of the worms when treated with different concentrations and compared to the negative (DMSO) and positive control (Triclabendazole). * Significant difference compared to DMSO controls (p < 0.05).
Surrogate selectivity was assessed by screening all synthesised compounds on HepG2 liver human cells using the MTT assay. Here, all diterpenoids showed moderate selectivity, being on average 3-5 times more toxic on blood or liver flukes than human cells (Tables 1 and 2 ).
Due to the veterinary importance of these parasitic diseases [9, 17, 28] , compounds were also screened against MDBK kidney bovine cells and showed a toxicity comparable or lower than that observed for HepG2 cells (Tables 1 and 2 ). 
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Looking at the difference in the anti-schistosomula activity of the analogues (where the most complete dataset has been collected), some trends in structure-activity relationship were found. Considering the non-cyclised analogues (1a-f and 2a-f), the alcohol series 1a-f was generally less active on schistosomula than the correspondent ketone series 2a-f. With regards to the aromatic portion, methoxy, iso-propyl and tert-butyl substitutions in position 12
(diterpenoid numeration from Figure 1 ) increased the anthelmintic activity when compared to the non-substituted analogues or to the ones with the methoxy group in 11 or 13. As a result, the most active compounds were 2c and 2d. This relationship was confirmed in the 7-keto series 8a-d with the most active compound being 8c. However, in the di-keto series 5a-c, the most active compound was 5b, which contained a methoxy group in position 13. This Swelling of the tegument is likely due to an osmotic effect after changes in the permeability of the membrane surface and/or in the osmoregulatory system, often linked to unbalanced ion distribution [30] . Even more pronounced was the damage of 7d to F. hepatica immature flukes, where a complete loss of spines on the ventral surface was observed together with sloughing of the tegument and exposure of the basal lamina ( Figure 7E and F).
These findings, together with other data reported in the literature [2, 31, 32] , support the hypothesis that one of the main targets of terpenoid like molecules is the tegument, a vital structure for anti-parasitic drugs because of its barrier function in host interactions [29] .
However, the decreased motility and the inhibition of phenotypically normal egg production could also indicate other possible mechanisms of action as hypothesised for 7ks [15] .
Conclusions
In conclusion, 30 analogues of the diterpenoid 7-keto-sempervirol were synthesised and 25 of them initially screened for anthelmintic activity on the larval stage of the parasite S.
mansoni. Amongst these 25 compounds, the best was 7d having an IC 50 of 6.8 -6.3 µM 
Experimental section
Chemistry
Commercial reagents and solvents were purchased from Sigma Aldrich or Fisher Scientific and used without further purification. 7-keto-sempervirol was obtained as previously described [15] . The synthesised compounds were characterized by high resolution mass HRMS, 
General method for synthesis of compounds 1a-f [19]
Under nitrogen, a mixture of naphthalene (3.75 eq) and lithium (3.75 eq) in anhydrous THF was stirred at room temperature for 2 h. Then, a solution of beta-cyclocitral (1.1 eq) and the substituted benzyl chloride (1 eq) was added dropwise via syringe at 0 °C. The reaction
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19 mixture was stirred at room temperature for 2 h, then diluted with diethyl ether and treated with saturated NH 4 Cl. The organic phase was separated and the aqueous phase extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (4-10% ethyl acetate in petroleum ether). 
General method for synthesis of compounds 2a-f
The previously obtained alcohol (1 eq) and N-methylmorpholine N-oxide (NMO) (1.5 eq)
were dissolved in anhydrous dichloromethane under nitrogen. After stirring for 15 minutes, tetrapropylammonium perruthenate (TPAP) (0.05 eq) dissolved in dichloromethane was added and the mixture stirred overnight. The reaction mixture was then diluted with dichloromethane, and washed with sodium sulphite solution and brine. The organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (4-10 % ethyl acetate in petroleum ether). 
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General method for synthesis of compounds 3a-c [19]
To a solution of the previously obtained ketone (1 eq) in anhydrous dichloromethane was added a solution of BBr 3 1 M (6 eq) in dichloromethane dropwise at -78 °C, under nitrogen.
The resulting mixture was stirred for 30 minutes and then allowed to reach 0 °C before continued stirring for 3 h. The reaction was quenched carefully with NaHCO 3 solution and the aqueous phase was extracted with ethyl acetate. Organic layers were washed with brine and dried over Na 2 SO 4 . The crude product was purified by silica gel column chromatography (5-30% ethyl acetate in petroleum ether). 
General method for synthesis of compounds 4a-c [20]
A mixture of AgOTf (0.4 eq) and RuCl 3 x H 2 O (0.2 eq) in dry dichloroethane was stirred for 1 h. The previously obtained ketone (1 eq) was then added and the resulting solution was stirred overnight at 80 °C. The solvent was evaporated and crude product purified by silica M A N U S C R I P T 
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General method for synthesis of compounds 5a-c
After exposure to air and light at room temperature for 2-7 days, changes in colour, from colourless to yellow, were noticed on the cis-6-keto compounds. The new di-keto compounds generated were isolated after purification by column chromatography (8-15%
ethyl acetate in petroleum ether). The oxidation procedure was repeated using the procedure followed for compounds 8a-c (see below). 
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General method for synthesis of compounds 7a-c [22]
A solution of R-BINOL (0.5 eq) in dry dichloromethane was cooled to -78 °C and then 1M 
General method for synthesis of compounds 8a-c
The previously obtained no-keto diterpenoid 7a-c was added dropwise to a solution of CrO 3
(1 eq) in acetic acid at room temperature. After overnight stirring, the reaction mixture was neutralized with NaHCO 3 and the aqueous phase extracted with diethyl ether. The organic layer was washed with brine, dried over Na 2 SO 4 and concentrated under reduced pressure.
The crude product was purified by silica gel column chromatography (2-5% ethyl acetate in petroleum ether). 
General method for synthesis of compounds 7d and 8d
To a solution of the previously obtained methoxy-diterpenoids (7b, 8b), a solution of 1M BBr 3 (6 eq) in dichloromethane at -78 °C was added dropwise under nitrogen. After stirring for 30 minutes, the reaction mixture was warmed to 0°C and stirred for 3 hours. The mixture was then neutralized with aqueous NaHCO 3 and the aqueous phase extracted with ethyl acetate.
The organic layer was washed with brine, dried over Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (10-15% ethyl acetate in petroleum ether) to afford the hydroxy-diterpenoids. 
Biological evaluation
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Compound handling and storage
In preparation for biological assays conducted, all compounds were solubilised in DMSO (Fisher Scientific, Loughborough, UK) and stored at -20°C at a stock concentration of 16mM.
Schistosoma mansoni schistosomula culture and compound screening
S. mansoni (Puerto Rican Strain, Naval Medical Research Institute -NMRI) cercariae were collected from infected Biomphalaria glabrata (NMRI) snails after exposure to 2 hours of light at 26 °C and then mechanically transformed into schistosomula as described [33] . Newly transformed schistosomula were prepared for 72 hour high throughput screening (HTS) in 384-well black-sided microtiter plates (Perkin Elmer, MA, USA) as described in Nur-e-Alam [24] , with a final DMSO concentration of 0.625%. The effect of compounds on 72 hour cultured schistosomula was deduced by analysing the effect on both motility and phenotype of treated schistosomula using the image analysis model described by Paveley [25] . While all worms were scored manually after 24hr, 48 hr and 72hr using microscopic methods described in the literature [35] , only motility metrics at 72hr are reported. At 72hr, eggs were M A N U S C R I P T
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26 also collected and counted from each well. After enumeration, eggs were finally subjected to fluorescence microscopy as described below. hours, the MTT assay was performed as previously described [24] .
Fasciola hepatica
Scanning Electron Microscopy and Fluorescence Microscopy
Following 72 hr co-culture with compounds at sub-lethal concentrations, parasites were processed for SEM analysis alongside those parasites derived from positive (Auranofin) and negative (DMSO) control wells. To separate male and female schistosomes for fixing and further SEM processing, several steps from Collins et al. were adapted [40] . Briefly, schistosomes were collected following treatment and washed in 1mL of anaesthetic (1% 
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In preparation for SEM analysis, all blood and liver fluke samples were then exposed to a number of wash, staining and dehydration steps before mounting for SEM. Initially, worms were washed twice in 0.1M sodium cacodylate for 30 minutes, and then stained in 1% osmium tetroxide solution (Agar Scientific, Stansted, UK) for 2 hours. Following staining, worms were then washed in 0.1M sodium cacodylate for 1 hour and then ultra-pure water for a further 30 minutes. Worms were then dehydrated using a 30, 50, 70, 95, 100% ethanol series (Fisher Scientific, Loughborough, UK) for 30 minutes each and then dried using hexamethyldisilazane critical drying point agent (Agar Scientific, Stansted, UK). Initially, worms were left in the drying agent for 3 hours. This was then removed and replaced with further drying agent, which was then allowed to evaporate off over night.
Once worm samples were fully dried, they were carefully mounted on self-adhesive conductive carbon tabs, on aluminium specimen stubs (both Agar Scientific, Stansted, UK) and then coated with gold using a Polaron E5000 SEM Coating Unit. Coated worms could then be stored in a desiccation jar until imaging. SEM imaging was conducted using a Hitachi S-4700 FESEM microscope (Ultra High Resolution, an accelerating voltage of 5.0kV
with a working distance of 5.0mm). Images were captured at 2560x1920 resolution.
After collection of schistosome worms for SEM analyses, media left in the wells were collected in separated Eppendorf tubes, spun down (200 x g for 2 minutes) and then carefully removed leaving a thin pellet of eggs at the bottom. Eggs were then fixed with 500 µl of 10% formaldehyde in PBS and stored at 3 -4 °C until use. Eggs were then transferred onto glass slides and visualised using a Leica LMD 6000 Laser Microdissection Microscope under natural light and GFP filter conditions.
Statistics
Multiple t-tests and Bonferroni post hoc test were used to determine any significant difference between each compound treatment and the DMSO control. Statistical tests and IC 50 calculations were performed using GraphPad Prism 7.02. 
